Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ottawa Hospital Research Institute
Age
19–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed primary breast cancer
Planned to start trastuzumab based neo/adjuvant therapy: FEC-DH or AC-DH, or; dose-dense AC-TH, or docetaxel/cyclophosphamide/trastuzumab or docetaxel/carboplatin/trastuzumab, or weekly paclitaxel with trastuzumab.
≥19 years of age
Able to provide verbal consent
You may not be if
Contraindication to central line placement.
Clareo Health | Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment.
